메뉴 건너뛰기




Volumn 16, Issue 8, 2015, Pages 928-936

Standard chemotherapy with or without bevacizumab for women with newly diagnosed ovarian cancer (ICON7): Overall survival results of a phase 3 randomised trial

(24)  Oza, Amit M a   Cook, Adrian D b   Pfisterer, Jacobus c   Embleton, Andrew b   Ledermann, Jonathan A d   Pujade Lauraine, Eric e   Kristensen, Gunnar f   Carey, Mark S g   Beale, Philip h   Cervantes, Andrés i   Park Simon, Tjoung Won j   Rustin, Gordon k   Joly, Florence l   Mirza, Mansoor R m   Plante, Marie n   Quinn, Michael o   Poveda, Andrés p   Jayson, Gordon C q   Stark, Dan r   Swart, Ann Marie s   more..


Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CARBOPLATIN; PACLITAXEL; ANTINEOPLASTIC AGENT; MONOCLONAL ANTIBODY;

EID: 84938198626     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(15)00086-8     Document Type: Article
Times cited : (688)

References (23)
  • 2
    • 84891372505 scopus 로고    scopus 로고
    • Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study
    • De Angelis R, Sant M, Coleman MP, et al. Cancer survival in Europe 1999-2007 by country and age: results of EUROCARE-5-a population-based study. Lancet Oncol 2014, 15:23-34.
    • (2014) Lancet Oncol , vol.15 , pp. 23-34
    • De Angelis, R.1    Sant, M.2    Coleman, M.P.3
  • 3
    • 80051913984 scopus 로고    scopus 로고
    • 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference
    • Stuart GC, Kitchener H, Bacon M, et al. 2010 Gynecologic Cancer InterGroup (GCIG) consensus statement on clinical trials in ovarian cancer: report from the Fourth Ovarian Cancer Consensus Conference. Int J Gynecol Cancer 2011, 21:750-755.
    • (2011) Int J Gynecol Cancer , vol.21 , pp. 750-755
    • Stuart, G.C.1    Kitchener, H.2    Bacon, M.3
  • 4
    • 85013312416 scopus 로고
    • Tumor angiogenesis: therapeutic implications
    • Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
    • (1971) N Engl J Med , vol.285 , pp. 1182-1186
    • Folkman, J.1
  • 5
    • 84855425106 scopus 로고    scopus 로고
    • Incorporation of bevacizumab in the primary treatment of ovarian cancer
    • Burger RA, Brady MF, Bookman MA, et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N Engl J Med 2011, 365:2473-2483.
    • (2011) N Engl J Med , vol.365 , pp. 2473-2483
    • Burger, R.A.1    Brady, M.F.2    Bookman, M.A.3
  • 6
    • 84855466019 scopus 로고    scopus 로고
    • A Phase 3 trial of bevacizumab in ovarian cancer
    • Perren TJ, Swart AM, Pfisterer J, et al. A Phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 2011, 365:2484-2496.
    • (2011) N Engl J Med , vol.365 , pp. 2484-2496
    • Perren, T.J.1    Swart, A.M.2    Pfisterer, J.3
  • 7
    • 84861736119 scopus 로고    scopus 로고
    • OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer
    • Aghajanian C, Blank SV, Goff BA, et al. OCEANS: a randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer. J Clin Oncol 2012, 30:2039-2045.
    • (2012) J Clin Oncol , vol.30 , pp. 2039-2045
    • Aghajanian, C.1    Blank, S.V.2    Goff, B.A.3
  • 8
    • 84899837376 scopus 로고    scopus 로고
    • Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial
    • Pujade-Lauraine E, Hilpert F, Weber B, et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial. J Clin Oncol 2014, 32:1302-1308.
    • (2014) J Clin Oncol , vol.32 , pp. 1302-1308
    • Pujade-Lauraine, E.1    Hilpert, F.2    Weber, B.3
  • 9
    • 84938207508 scopus 로고    scopus 로고
    • The Electronic Medicines Compendium, (accessed Nov 18, 2014).
    • Avastin 25mg/ml concentrate for solution for infusion The Electronic Medicines Compendium, (accessed Nov 18, 2014). https://www.medicines.org.uk/emc/medicine/15748/SPC/Avastin+25mg+ml+concentrate+for+solution+for+infusion/.
    • Avastin 25mg/ml concentrate for solution for infusion
  • 10
    • 84938211289 scopus 로고    scopus 로고
    • US Food and Drug Administration, (accessed Nov 18, 2014).
    • Bevacizumab solution in combination with paclitaxel US Food and Drug Administration, (accessed Nov 18, 2014). http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm423159.htm.
    • Bevacizumab solution in combination with paclitaxel
  • 11
    • 0034594628 scopus 로고    scopus 로고
    • New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada
    • Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 2000, 92:205-216.
    • (2000) J Natl Cancer Inst , vol.92 , pp. 205-216
    • Therasse, P.1    Arbuck, S.G.2    Eisenhauer, E.A.3
  • 12
    • 0037102914 scopus 로고    scopus 로고
    • Flexible poportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects
    • Royston P, Parmar MKB Flexible poportional-hazards and proportional-odds models for censored survival data, with application to prognostic modelling and estimation of treatment effects. Stat Med 2002, 21:2175-2197.
    • (2002) Stat Med , vol.21 , pp. 2175-2197
    • Royston, P.1    Parmar, M.K.B.2
  • 13
    • 84894044956 scopus 로고    scopus 로고
    • Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC)
    • Witteveen P, Lortholary A, Fehm T, et al. Late breaking abstract: final overall survival (OS) results from AURELIA, an open-label randomised phase III trial of chemotherapy (CT) with or without bevacizumab (BEV) for platinum-resistant recurrent ovarian cancer (OC). Eur J Cancer 2013, 49(suppl 3):S3-S4.
    • (2013) Eur J Cancer , vol.49 , pp. S3-S4
    • Witteveen, P.1    Lortholary, A.2    Fehm, T.3
  • 14
    • 84938098476 scopus 로고    scopus 로고
    • A phase III randomised controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (GOG-0213)
    • Coleman R, Brady M, Herzog T, et al. A phase III randomised controlled clinical trial of carboplatin and paclitaxel alone or in combination with bevacizumab followed by bevacizumab and secondary cytoreductive surgery in platinum-sensitive, recurrent ovarian, peritoneal primary and fallopian tube cancer (GOG-0213). Gynecol Oncol 2015, 137(suppl 1):3.
    • (2015) Gynecol Oncol , vol.137 , pp. 3
    • Coleman, R.1    Brady, M.2    Herzog, T.3
  • 15
    • 84871720057 scopus 로고    scopus 로고
    • Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial
    • Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013, 14:29-37.
    • (2013) Lancet Oncol , vol.14 , pp. 29-37
    • Bennouna, J.1    Sastre, J.2    Arnold, D.3
  • 16
    • 84908126746 scopus 로고    scopus 로고
    • Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial
    • von Minckwitz G, Puglisi F, Cortes J, et al. Bevacizumab plus chemotherapy versus chemotherapy alone as second-line treatment for patients with HER2-negative locally recurrent or metastatic breast cancer after first-line treatment with bevacizumab plus chemotherapy (TANIA): an open-label, randomised phase 3 trial. Lancet Oncol 2014, 15:1269-1278.
    • (2014) Lancet Oncol , vol.15 , pp. 1269-1278
    • von Minckwitz, G.1    Puglisi, F.2    Cortes, J.3
  • 17
    • 70349878651 scopus 로고    scopus 로고
    • Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial
    • Katsumata N, Yasuda M, Takahashi F, et al. Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 2009, 374:1331-1338.
    • (2009) Lancet , vol.374 , pp. 1331-1338
    • Katsumata, N.1    Yasuda, M.2    Takahashi, F.3
  • 18
    • 84897380455 scopus 로고    scopus 로고
    • Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262
    • Chan J, Brady M, Penson R, et al. Phase III trial of every-3-weeks paclitaxel vs. dose dense weekly paclitaxel with carboplatin +/- bevacizumab in epithelial ovarian, peritoneal, fallopian tube cancer: GOG 262. Int J Gynecol Cancer 2013, 23(8 suppl 1):9-10.
    • (2013) Int J Gynecol Cancer , vol.23 , Issue.8 SUPPL 1 , pp. 9-10
    • Chan, J.1    Brady, M.2    Penson, R.3
  • 19
    • 84875248912 scopus 로고    scopus 로고
    • Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial
    • Stark D, Nankivell M, Pujade-Lauraine P, et al. Standard chemotherapy with or without bevacizumab in advanced ovarian cancer: quality-of-life outcomes from the International Collaboration on Ovarian Neoplasms (ICON7) phase 3 randomised trial. Lancet Oncol 2013, 14:236-243.
    • (2013) Lancet Oncol , vol.14 , pp. 236-243
    • Stark, D.1    Nankivell, M.2    Pujade-Lauraine, P.3
  • 20
    • 84884562902 scopus 로고    scopus 로고
    • Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection
    • Collinson F, Hutchinson M, Craven RA, et al. Predicting response to bevacizumab in ovarian cancer: a panel of potential biomarkers informing treatment selection. Clin Cancer Res 2013, 19:5227-5239.
    • (2013) Clin Cancer Res , vol.19 , pp. 5227-5239
    • Collinson, F.1    Hutchinson, M.2    Craven, R.A.3
  • 21
    • 84964314560 scopus 로고    scopus 로고
    • The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer
    • Backen A, Renehan AG, Clamp AR, et al. The combination of circulating Ang1 and Tie2 levels predicts progression-free survival advantage in bevacizumab-treated patients with ovarian cancer. Clin Cancer Res 2014, 20:4549-4558.
    • (2014) Clin Cancer Res , vol.20 , pp. 4549-4558
    • Backen, A.1    Renehan, A.G.2    Clamp, A.R.3
  • 22
    • 84908319663 scopus 로고    scopus 로고
    • Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab
    • Gourley C, McCavigan A, Perren T, et al. Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. Proc Am Soc Clin Oncol 2014, 32(5 suppl). abstr 5502.
    • (2014) Proc Am Soc Clin Oncol , vol.32 , Issue.5
    • Gourley, C.1    McCavigan, A.2    Perren, T.3
  • 23
    • 84903543603 scopus 로고    scopus 로고
    • Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer
    • Winterhoff BJN, Kommoss S, Oberg A, et al. Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. Proc Am Soc Clin Oncol 2014, 32(5 suppl). abstr 5509.
    • (2014) Proc Am Soc Clin Oncol , vol.32 , Issue.5
    • Winterhoff, B.J.N.1    Kommoss, S.2    Oberg, A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.